Medical Devices Hong Kong

Hong Kong Pharmacogenomic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Hong Kong Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.6 Mn Placeholder estimate
Estimate 2025 $5.1 Mn 0.2% of the global market
Projected 2034 $12.9 Mn 155.8% Adds $7.9 Mn over 9 forecast years
CAGR 2025–2034 11.0% Faster than 60% of 173 Medical Devices markets here
Key players 5
  • Hong Kong is 0.16% of the global market.
  • In APAC, the largest is Japan at $225.2 Mn.
  • Fastest growing: India at 13% a year.
  • Hong Kong ranks 8th of 10 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$7.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.6 Mn — —
2025 (base) $5.1 Mn +$0.5 Mn —
2026 (forecast) $5.6 Mn +$0.6 Mn +11%
2027 (forecast) $6.2 Mn +$0.6 Mn +23.2%
2028 (forecast) $6.9 Mn +$0.7 Mn +36.8%
2029 (forecast) $7.7 Mn +$0.8 Mn +51.8%
2030 (forecast) $8.5 Mn +$0.8 Mn +68.5%
2031 (forecast) $9.4 Mn +$0.9 Mn +87%
2032 (forecast) $10.5 Mn +$1.0 Mn +107.6%
2033 (forecast) $11.6 Mn +$1.2 Mn +130.5%
2034 (forecast) $12.9 Mn +$1.3 Mn +155.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong Pharmacogenomic Testing Market Analysis at a glance
Market size, 2025$5.1 Mn placeholder estimate
Forecast, 2034$12.9 Mn placeholder estimate
Growth (CAGR), 2025–203411.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all)
Regulator in Hong KongMDACSSource: Medical Device Division, Department of Health. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong Pharmacogenomic Testing Market Analysis Executive Summary

Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.

Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).

Bar chart: Hong Kong Pharmacogenomic Testing market size, 2024–2034, placeholder estimates. $4.6 Mn in 2024, $5.1 Mn in 2025 and $12.9 Mn in 2034, 11.0% CAGR.
Hong Kong Pharmacogenomic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong Pharmacogenomic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.

Competitive Landscape for Pharmacogenomic Testing Market in Hong Kong

The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing Market in Hong Kong

Pharmacogenomic Testing in Hong Kong: rules and payment

Hong Kong has a voluntary listing system for medical devices (MDACS), run by the Medical Device Division of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2]

[1] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Hong Kong.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing market in Hong Kong?
Placeholder estimate: about $5.1 Mn in 2025, rising to about $12.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing market in Hong Kong growing?
Placeholder estimate: about 11.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Psychiatry, Cardiology, Oncology, Pain Management) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing market?
Key players include Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc. and RPRD Diagnostics.
What is driving the Pharmacogenomic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Who regulates Pharmacogenomic Testing in Hong Kong?
Hong Kong has a voluntary listing system for medical devices (MDACS), run by the Medical Device Division of the Department of Health. Source: Medical Device Division, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How much research is published on Pharmacogenomic Testing?
PubMed lists 369 papers on Pharmacogenomic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Hong Kong

See all

Related on genomics and diagnostics and lab testing

See the topic